# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-28-2024 | 12-31-2023 | 10-K | |
2 | 11-09-2023 | 09-30-2023 | 10-Q | |
3 | 08-14-2023 | 06-30-2023 | 10-Q | |
4 | 06-15-2023 | 03-31-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar maintains Acelyrin (NASDAQ:SLRN) with a Buy and lowers the price target from $2...
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $28 price target.
Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.99) by 2...
Wells Fargo analyst Derek Archila maintains Acelyrin (NASDAQ:SLRN) with a Equal-Weight and raises the price target from $11 ...
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated wit...
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $30 price target.
HC Wainwright & Co. analyst Emily Bodnar reiterates Acelyrin (NASDAQ:SLRN) with a Buy and maintains $30 price target.